E3 ubiquitin-protein transferase MAEA (MAEA)

MAEA (Macrophage Erythroblast Attachement Antigen), also known as E3 ubiquitin-protein transferase MAEA, is a protein that functions as a component of the E3 ubiquitin ligase complex, specifically as a subunit of the GID E3 ubiquitin ligase complex in humans. It mediates the ubiquitination of target proteins, marking them for proteasomal degradation. This activity is crucial for a variety of cellular processes, including cell proliferation, cell cycle regulation, apoptosis, immune responses (such as macrophage differentiation), and cell adhesion. Dysregulation of MAEA has been implicated in several diseases, most notably various cancers, where it can influence tumor growth, invasion, and metastasis. Its precise role can be context-dependent, sometimes acting as an oncogene and other times as a tumor suppressor. Due to its essential cellular functions and involvement in disease, MAEA is considered a potential therapeutic target, although direct small-molecule modulators are not yet in clinical use.

Other names

MAEAEMPHLC10PIG5HLC-10GID9p44EMLPCell proliferation

No specific drugs directly targeting MAEA are currently known or in clinical use. Therapeutic strategies would likely involve modulating its E3 ubiquitin ligase activity to impact the stability of its substrates and downstream cellular pathways.